Literature DB >> 10955342

Validation of a German version of the Fibromyalgia Impact Questionnaire (FIQ-G).

M Offenbaecher1, M Waltz, P Schoeps.   

Abstract

OBJECTIVE: To translate the Fibromyalgia Impact Questionnaire (FIQ) into German and to evaluate its reliability and validity for the use of German speaking patients with fibromyalgia (FM).
METHODS: We administered the FIQ to 55 patients with FM (15 patients filled out the questionnaire 10 days later) together with German versions of the Stanford Health Assessment Questionnaire (HAQ), the Medical Outcomes Survey Short Form-36 (SF-36), and a tender point count (TPC). All patients were asked about the severity of pain today (10 cm visual analog scale) and the duration of symptoms. Tenderness thresholds were assessed by dolorimetry at all tender points with a Fisher dolorimeter and laboratory tests were obtained. Test-retest reliability was assessed using Spearman correlations. Internal consistency was evaluated with Cronbach's alpha of reliability. Construct validity of the FIQ was evaluated by correlating the HAQ and subscales of the SF-36 as well as the TPC and the tenderness thresholds.
RESULTS: Mean age of participants was 54.3 years and mean duration of symptoms 9.5 years. Test-retest reliability was between 0.62 and 1 for the physical functioning as well as for the total FIQ and other components. Internal consistency was 0.92 for the overall FIQ. Significant correlations were obtained between the FIQ items, the HAQ, and the SF-36.
CONCLUSION: The German FIQ is a reliable and valid instrument for measuring functional disability and health status in German patients with FM.

Entities:  

Mesh:

Year:  2000        PMID: 10955342

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  36 in total

1.  [Pharmacological treatment of fibromyalgia syndrome].

Authors:  C Sommer; W Häuser; M Berliner; W Brückle; S Ehlers; K Mönkemöller; B Moradi; F Petzke; N Uçeyler; R Wörz; E Winter; D O Nutzinger
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

Review 2.  [Fibromyalgia syndrome: new developments in pharmacotherapy].

Authors:  P Harten
Journal:  Z Rheumatol       Date:  2008-02       Impact factor: 1.372

3.  Serum lipid profile in fibromyalgia women.

Authors:  Gulcan Gurer; Omer Faruk Sendur; Cavidan Ay
Journal:  Clin Rheumatol       Date:  2005-10-01       Impact factor: 2.980

4.  Treatment-related changes in brain activation in patients with fibromyalgia syndrome.

Authors:  Martin Diers; Pinar Yilmaz; Mariela Rance; Kati Thieme; Richard H Gracely; Claudia Rolko; Marcus T Schley; Ulrike Kiessling; Haili Wang; Herta Flor
Journal:  Exp Brain Res       Date:  2012-03-17       Impact factor: 1.972

5.  Quality of life in patients with fibromyalgia: validation and psychometric properties of the German Quality of Life Scale (QOLS-G).

Authors:  Martin Offenbächer; Sebastian Sauer; Niko Kohls; Millard Waltz; Peter Schoeps
Journal:  Rheumatol Int       Date:  2011-10-30       Impact factor: 2.631

6.  Classifying Fibromyalgia Syndrome as a Mental Disorder?-An Ambulatory Assessment Study.

Authors:  Kristina Klaus; Susanne Fischer; Johanna M Doerr; Urs M Nater; Ricarda Mewes
Journal:  Int J Behav Med       Date:  2017-04

7.  [Evaluation of effectiveness of education in rheumatology : Recommendations according to a patient education model].

Authors:  A Reusch; G Musekamp; R Küffner; M Dorn; J Braun; I Ehlebracht-König
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

Review 8.  Fibromyalgia: an overview.

Authors:  Diane Thompson; Louise Lettich; Junji Takeshita
Journal:  Curr Psychiatry Rep       Date:  2003-07       Impact factor: 5.285

9.  [Whole body hyperthermia in pain therapy. A controlled trial on patients with fibromyalgia].

Authors:  J Walz; J Hinzmann; I Haase; T Witte
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

10.  Validation of the International Classification of Functioning, Disability and Health Core Set for chronic widespread pain from the perspective of fibromyalgia patients.

Authors:  Robin Hieblinger; Michaela Coenen; Gerold Stucki; Andreas Winkelmann; Alarcos Cieza
Journal:  Arthritis Res Ther       Date:  2009-05-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.